



Overview

Prescient Therapeutics Limited (ASX:PTX) is a clinical stage oncology company developing two targeted therapies that address specific mutations that drive cancer and contribute to resistance – namely Akt, Ras and Rho mutations. Both drugs emanate from prestigious US institutions, and all clinical work is currently undertaken in the US at prominent cancer centres.

PTX is currently conducting or several clinical trials in breast cancer (Phase 2); acute myeloid leukemia (Phase 1b/2) and ovarian cancer (Phase 1b/2 trial). Very encouraging efficacy signals were recently observed in the recent breast cancer study, with 100% of locally advanced breast cancer patients responding.

PTX is also planning a transformative trial with PTX-100 with Rho and Ras mutant cancers.

Speaker Profile

Steven Yatomi-Clarke, Chief Executive Officer and Managing Director



Mr Yatomi-Clarke was appointed as CEO and Managing Director of Prescient Therapeutics in February 2016, having previously been a Non-executive Director of the Company.

With a background in molecular biology, biochemistry, Mr Yatomi-Clarke has over 17 years' experience investment banking, healthcare and biotechnology, where he was consistently one of the most prolific and

successful bankers, involved in primary and secondary offerings, corporate advisory and mergers and acquisitions assignments for pharmaceutical and medical device companies.

Mr Yatomi-Clarke has also been a collaborator on clinical trials conducted in Australia and the US in the field of cancer immunotherapy, with the rare distinction of readily bridging the divide between science and commerce.

Steven holds a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor of Commerce majoring in Economics, both from the University of Melbourne.